A Vanderbilt University Medical Center Alumni Publication

Vanderbilt Medicine

facebook rss digg
AROUND THE MEDICAL CENTER :: WINTER 2014
PRINT

Blood test for autism could speed diagnosis


By Craig Boerner
August 2013

Vanderbilt University is part of a multi-site autism clinical study designed to evaluate the effectiveness of a blood test that aims to screen children for referral for autism spectrum disorder (ASD) evaluation earlier and more accurately.


“The best outcome would be a test that can be used to help identify children at risk who can then receive a definitive evaluation,” said Vanderbilt site co-investigator Jeremy Veenstra-VanderWeele, M.D., associate professor of Psychiatry, Pediatrics and Pharmacology.


“We don’t need another 10 studies that are in small samples saying this approach might be useful. We need one study that says, ‘Yes, it is’ or ‘No, it’s not’ and this study is designed to do that.”


Screening children for a possible ASD is currently an uncertain process, with pediatricians sometimes using symptom checklists but more often relying on clinical exams or parents’ expression of concerns. In part as a result of inadequate screening, the average age of diagnosis of ASD is 4.5 years old, despite symptoms typically emerging before age 2.


“There is an ever growing body of research suggesting that appropriately intensive early intervention can dramatically shift outcomes for children with ASD,” said Vanderbilt principal investigator Zachary Warren, Ph.D., associate professor of Pediatrics, Psychiatry and Special Education. “As a field we are really hoping to develop measures and systems of care that can accurately identify children with ASD at very young ages.”


The 660-child, 20-site, clinical study in the United States and Canada is funded by the SynapDx Corp and also includes Boston Children’s Hospital, Mount Sinai Hospital, Nationwide Children’s Hospital and the University of California-Davis MIND Institute.


SynapDx’s blood test measures differences in RNA gene expression to provide families with an ASD risk factor for their child to help clinicians make faster, more accurate referral decisions.


“It is a simple blood draw, and they are looking at gene expression changes in blood cells. In this case you are looking at white blood cells to see what genes are expressed at what level,” Veenstra-VanderWeele said. “These changes won’t be diagnostic, but they will allow a calculation of risk for an individual child.” 

©2009 Vanderbilt Medical Center
Editorial tool created by Vanderbilt Medical Center Web Development
Vanderbilt University is committed to principles of equal opportunity and affirmative action.